Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Grb2 SH2 domain-binding peptide analogs as potential anticancer agents.

Feng-Di T Lung1, Jya-Yin Tsai

  • 1Department of Nutrition, China Medical College 91, Hsueh-Shih Road, Taichung 404, Taiwan, Republic of China. fdlung@mail.cmc.edu.tw

Biopolymers
|May 27, 2003
PubMed
Summary

Researchers are developing Grb2 SH2 domain inhibitors as anticancer agents. These peptide-based drugs target the Ras signaling pathway, offering a promising strategy for cancer therapy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Designing the antimicrobial peptide with centrosymmetric and amphipathic characterizations for improving antimicrobial activity.

Journal of peptide science : an official publication of the European Peptide Society·2023
Same author

Structure activity relationships of peptidic analogs of MyoD for the development of Id1 inhibitors as antiproliferative agents.

Journal of peptide science : an official publication of the European Peptide Society·2013
Same author

Anticancer activities of an antimicrobial peptide derivative of Ixosin-B amide.

Bioorganic & medicinal chemistry letters·2013
Same author

Structure-activity relationship of potent antimicrobial peptide analogs of Ixosin-B amide.

Bioorganic & medicinal chemistry letters·2013
Same author

Discovery of potent antimicrobial peptide analogs of Ixosin-B.

Bioorganic & medicinal chemistry letters·2012
Same author

Structure-activity relationships of a peptidic antagonist of Id1 studied by biosensor method, circular dichroism spectroscopy, and bioassay.

Journal of peptide science : an official publication of the European Peptide Society·2011

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Background:

  • Growth factor receptor-bound protein 2 (Grb2) is crucial in the Ras signaling pathway.
  • Overexpressed proteins in this pathway make Grb2 a target for antitumor agents.
  • Blocking Grb2's SH2 domain interaction is a key anticancer strategy.

Purpose of the Study:

  • To review approaches for developing Grb2 SH2 peptide inhibitors.
  • To explore strategies for interrupting Grb2 recognition in cancer signaling.

Main Methods:

  • Structure-based design utilizing X-ray, NMR, and molecular modeling of the Grb2 SH2 domain.
  • Development of peptide and peptidomimetic inhibitors.
  • Assays including ELISA, cell-based assays, and Surface Plasmon Resonance (SPR) to determine inhibitory effects and binding affinities.

Related Experiment Videos

Main Results:

  • Structural data facilitates the design of high-affinity inhibitors for the Grb2 SH2 domain.
  • Various peptide analogs have been developed to inhibit Grb2 recognition.
  • Studies provide data on inhibitory effects and binding affinities.

Conclusions:

  • Peptide inhibitors targeting the Grb2 SH2 domain are a viable approach for anticancer drug development.
  • Further modifications of lead peptides can lead to potent anticancer agents.
  • Interrupting Grb2 recognition offers a promising therapeutic strategy.